GLP1R and Parkinson disease: Accumulating data revealed that the administration of GLP-1 receptor agonist (GLP-1 RA) not only alleviates traumatic or ischemic brain damage [2,3] but also ameliorates neurodegenerative diseases demonstrated in Alzheimer’s disease (AD) and Parkinson’s disease mice models [4,5] through reduced neuronal cell death and microglial activation.